Das Gaurav, Talukdar Amrita, Bhutia Karma, Talukdar Abhijit
Department of Surgical Oncology, Dr. B. Borooah Cancer Institute (a unit of Tata Memorial Centre), Room No. 30, AK Azad Road, Gopinath Nagar, Guwahati, Assam 781016 India.
Department of Microbiology, Dr. B. Borooah Cancer Institute (a unit of Tata Memorial Centre), AK Azad Road, Gopinath Nagar, Guwahati, Assam 781016 India.
Indian J Surg Oncol. 2023 Dec;14(4):876-880. doi: 10.1007/s13193-023-01797-7. Epub 2023 Jul 7.
The aim of our study was to report about the clinical outcomes of patients who underwent major surgery for cancer and developed COVID-19 in the postoperative period. A retrospective and observational study was done in the Surgical Oncology Division of a tertiary care cancer hospital in North-East India. The study period was from 1 April 2020 to 31 December 2021. Patients with a confirmed diagnosis of cancer who underwent a major surgery and developed COVID-19 in the postoperative period, within the same hospital stay were included in the study. Data was obtained from a prospectively maintained database and case records. Descriptive statistics were used to state the results in median values, range and percentages. A total of 22 patients developed COVID-19 in the postoperative period during the study period out of a total of 1402 patients operated during that time period (1.57%). The have been followed up for a median period of 16 months (range 2 to 18 months). The median age at presentation was 50 years (range 25 to 74 years). The incidence of co-morbidities was 27.3%. The median duration of ICU stay was 3 days (range 0 to 9 days) and median duration of hospital stay was 22 days (range 9 to 55 days).. The postoperative mortality rate was 18.2%. COVID-19 in the postoperative period in patients undergoing major abdominal and thoracic surgeries for cancer caused high postoperative mortality and prolonged hospital stay.
我们研究的目的是报告接受癌症大手术且术后发生新型冠状病毒肺炎(COVID-19)的患者的临床结局。在印度东北部一家三级护理癌症医院的外科肿瘤学部进行了一项回顾性观察研究。研究期间为2020年4月1日至2021年12月31日。在同一住院期间接受大手术且术后发生COVID-19的确诊癌症患者纳入本研究。数据来自前瞻性维护的数据库和病例记录。使用描述性统计以中位数、范围和百分比说明结果。在该时间段内接受手术的1402例患者中,共有22例在术后发生COVID-19(1.57%)。对其进行了中位时间为16个月(范围2至18个月)的随访。就诊时的中位年龄为50岁(范围25至74岁)。合并症发生率为27.3%。重症监护病房(ICU)住院时间的中位数为3天(范围0至9天),住院时间的中位数为22天(范围9至55天)。术后死亡率为18.2%。接受癌症腹部和胸部大手术患者术后发生的COVID-19导致了较高的术后死亡率和延长的住院时间。